Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantJH
Janus Henderson Investors
Activity from announced rounds
Activity in this selectionepisode1-ventures-13603d62
Janus Henderson Investors is the investment manager named by Epicrispr as co-lead and by Form Energy as a new investor.
Recorded funding activity
Epicrispr develops programmable epigenetic medicines. Form develops multi-day iron-air batteries, while Encoded develops neurological gene therapies. The event announcements identify the manager without naming an individual Janus fund.
Sources
- Rounds participated in
- 15
- Confirmed lead rounds
- 0 12 roles undisclosed
- New companies
- 15 First participation on record · 0 follow-on
- Funding in participating rounds
- $2.6B 15 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
15 in this selectionFORM ENERGY
Long-duration iron-air batteries designed to store electricity for multi-day grid needs.
$750MSeries G
ParticipantEpicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedDraig Therapeutics
Draig Therapeutics develops neuropsychiatric medicines.
$65MSeries B
Role not disclosedTriveni Bio
Develops novel antibody treatments for immunological and inflammatory disorders
$65MSeries C
Role not disclosedCalyxo
Develops medical devices for kidney stone treatment and removal
$40MSeries F
Role not disclosedAmbrosia Biosciences
Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.
$100MSeries B
ParticipantPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$45MSeries A+
Role not disclosedKorsana Biosciences
Develops therapies for neurodegenerative diseases.
$175MSeries A
Role not disclosedILiAD Biotechnologies
Developing a next-generation pertussis vaccine candidate BPZE1
$115MSeries B
Role not disclosedCesiumAstro
CesiumAstro develops communications technology for space and defense applications.
$470MSeries C
Role not disclosedTRex Bio
Develops precision immunoregulatory medicines based on tissue Treg biology
$50MUndisclosed
Role not disclosedThink Bioscience
Develops small molecule drugs for historically challenging drug targets
$55MSeries A
Role not disclosedCaldera Therapeutics
Develops bispecific antibody CLD-423 for inflammatory bowel disease
$37.5MSeries A1
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed